![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 19, 14415-14422, May 12, 2000
From the Signal Transduction Laboratory, Institute of Molecular and Cell Biology, 30 Medical Dr., Singapore 117609, Republic of Singapore
| |
ABSTRACT |
|---|
|
|
|---|
We recently identified BNIP-2, a previously
cloned Bcl-2- and E1B-associated protein, as a putative substrate of
the FGF receptor tyrosine kinase and showed that it possesses
GTPase-activating activity toward Cdc42 despite the lack of homology to
previously described catalytic domains of GTPase-activating proteins
(GAPs). BNIP-2 contains many arginine residues at the carboxyl
terminus, which includes the region of homology to the noncatalytic
domain of Cdc42GAP, termed BNIP-2 and Cdc42GAP
homology (BCH) domain. Using BNIP-2 glutathione
S-transferase recombinants, it was found that its BCH bound
Cdc42, and contributed the GAP activity. This domain was predicted to
fold into Ras superfamily GTPase proteins act as molecular switches for
signal transduction pathways to control cell growth, differentiation, and motility. The Ras superfamily consists of the Ras, Rho, Rab, and
Arf families, which are classified according to their sequence similarities and functions (1, 2). These proteins cycle between two
guanine-nucleotide bound states, the GTP-bound form, which is active,
and the inactive GDP-bound form. Activation occurs as a result of a
change in the conformation of discrete "switch regions" in these
proteins that allow them to interact with their appropriate effector
proteins. The GTP/GDP-regulated proteins possess a low intrinsic
activity for hydrolyzing GTP to GDP, but for efficient physiological
catalysis, they associate with other proteins, which can enhance their
GTPase activity further. These proteins are termed GTPase-activating
proteins (GAPs),1 and they
have been recognized by conserved amino acid sequence motifs that
are characteristic of each family (3).
The Rho subfamily of GTPases, which includes RhoA, RhoB, RhoC, RhoE,
RhoG, Rac1, Rac2, Cdc42, and TC10, is involved in various aspects of
cytoskeletal organization, cell polarity, and motility (4-6). For
example, RhoA is involved in the regulation of stress fibers and focal
adhesion formation (7, 8), Rac1 is involved in the formation of
lamellipodia and membrane ruffling (9, 10), and Cdc42 is necessary for
actin microspikes/filopodia to form (10, 11). Furthermore, all three
can activate the Jun amino-terminal kinase, affect the transcription of
certain target genes, and regulate the progression of the cell cycle
(12, 13). Structural and biochemical studies show that all GAPs, although bearing no close overall sequence homology to each other, exert their effect either by contributing catalytic residues
in-trans, by lowering the activation energy for GTP
hydrolysis, or by stabilizing the conformation of the inherent GTPases.
These mechanisms are employed by 120-kDa RasGAP and the 50-kDa
RhoGAP/Cdc42GAP through a highly conserved arginine "finger"
catalytic motif and by similar binding topology (3, 14-22). Recently,
however, the crystal structure of rna1p, the Schizosaccharomyces
pombe ortholog of the mammalian GAP of Ran, revealed a completely
different folding pattern that nevertheless contributed to both the
catalysis and the stabilization effect on Ran (23).
GAPs have been identified that act preferentially on members of the Rho
subfamily. It is interesting to note that two different catalytic
domains have been described for GAPs acting on Cdc42. The 50-kDa
Cdc42GAP was shown in various crystallographic studies to possess the
conventional arginine finger that interacted closely with the Switch I
domain from Cdc42 to affect catalysis. The second type of catalytic
domain, albeit of unproven physiological relevance, was identified when
Cdc42 forms a homodimer. In this circumstance, one molecule can act as
a GAP toward the other partner, with catalysis being mediated by a
conserved arginine patch in the carboxyl terminus (24, 25).
We have recently shown BNIP-2, a previously cloned Bcl-2 interacting
protein, to be a putative substrate of the FGF receptor tyrosine kinase
and to bind both Cdc42GAP and Cdc42 when not tyrosine-phosphorylated. Interestingly, BNIP-2 was also shown to possess a "GAP-like"
activity toward Cdc42 (26). This protein contains no sequence homology to the canonical catalytic domain of a GAP, but it shares a highly conserved sequence with a region in the amino-terminal, noncatalytic half of Cdc42GAP (26, 27). We wished to determine the sequences in
BNIP-2 that were responsible for the binding to Cdc42 and for the
catalysis. To do this, we used a combination of site-directed mutagenesis and molecular modeling based on both the known biochemistry and structural topology of the catalytic Cdc42GAP domains. It enabled a
hypothetical model to be constructed that formed the basis for the
mutational studies. Using this approach, we have found that the
BNIP-2 and Cdc42GAP homology (BCH)
domain contains the GAP activity in BNIP-2, but not in Cdc42GAP. Within
this novel domain, there are two critical arginine residues that are
important for conferring the GAP activity. This arginine patch shares
reasonable similarity to those residues that mediate the
homodimerization-induced GAP activity seen with Cdc42 homodimers (24,
25). Other discrete regions likely to be important for the BNIP-2 and
Cdc42 interaction were also identified.
Plasmids--
Full-length cDNA of BNIP-2 was cloned into a
hemagglutinin (HA)-tagged expression vector, pXJ40 (Dr. E. Manser,
Institute of Molecular and Cell Biology, Singapore), or into pGEX4T-1
vector for producing the GST recombinant protein as described
previously (26). pGEX-Cdc42 and pGEX-Cdc42GAP (from Dr. A. Hall,
University College London, United Kingdom) were used in making GST
fusion proteins or as templates to generate pXJ40HA and pXJ40FLAG
constructs. Point mutants of BNIP-2 or Cdc42 were generated by
site-directed mutagenesis using the Quick-Change mutagenesis kit
(Stratagene), whereas deletion mutants were generated by polymerase
chain reaction using specific primers facilitated by restriction sites.
All plasmids were purified using a Wizard Miniprep kit (Promega) or a
Wizard Maxi/Mega-prep kit followed by ethanol reprecipitation for use in transfection experiments. Clones were confirmed correct by thermal-cycle sequencing using the SequiThermal EXCEL II DNA sequencing kit (Epicentre Technologies) or mapping analyses using restriction enzymes (New England Biolabs). Escherichia coli strain
DH5 Cell Culture and Transfection--
Human 293T cells were grown
in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum
(Hyclone), 2 mM L-glutamine, 100 units/ml
penicillin, and 100 µg/ml streptomycin (all from Sigma) and
maintained at 37 °C in a 5% CO2 atmosphere. Cells at 90% confluence in 100-mm plates were transfected for 1 h with 10 µg of indicated plasmid using Tfx-50 cationic lipids according to the
manufacturer's instructions (Promega).
Precipitation Experiments and Western Blot Analyses--
Cells
were lysed in 1 ml of lysis buffer (50 mM HEPES, pH 7.4, 150 mM sodium chloride, 1.5 mM magnesium
chloride, 5 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton
X-100, a mixture of proteases inhibitors (Roche Molecular
Biochemicals), and 5 mM sodium orthovanadate). The lysates
were directly analyzed as either whole cell lysates (25 µg) or their
aliquots (500 µg) were used in affinity precipitation/pulldown experiments with GST-BNIP-2 (5 µg) or GST-Cdc42 (5 µg) that had been preloaded with guanosine 5'-O-3-thiotriphosphate
(GTP GAP Assay--
The GAP activity toward Cdc42 was examined by
determining the release of 32Pi from the
[ Comparative Molecular Modeling--
Atomic coordinates for the
catalytic GAP domain of Cdc42GAP and p85-BH were obtained from the
Research Collaboratory for Structural Bioinformatics Protein Data Bank
(Protein Data Bank codes 2NGR and 1PBW, respectively) and used as
templates for molecular modeling as described previously (28). The
alignment between the amino acid sequences of p85-BH, the catalytic GAP
domain of Cdc42GAP, BNIP2-BCH, and Cdc42GAP-BCH was obtained using
ClustalW1.7 (54) followed by manual adjustment. Using LOOK (Molecular
Application Group), the aligned amino acid sequence of BNIP2-BCH was
substituted onto the averaged backbone atomic coordinates of p85-BH and
Cdc42GAP. The predicted structure was then energy-minimized with a
restrained and full conjugate gradient geometry optimization using the
molecular modeling software SYBYL 6.4 performed on a UNIX workstation
model IRIS/indigo (Silicon Graphics Inc., Mountain View, CA).
BNIP-2 Binding to Cdc42--
We previously demonstrated that
BNIP-2 acts as a GAP protein toward Cdc42, despite its lack of obvious
homology to the canonical GAP domain for Cdc42 (26). To gain an insight
into the structural/functional relationship between BNIP-2 and Cdc42,
we initially set out to identify which regions of BNIP-2 bind to Cdc42.
Full-length and various deletion constructs of BNIP-2 were generated as
GST recombinants as indicated (Fig.
1A). The full-length protein
was arbitrarily dissected into various fragments designated as A, B,
BCH, C1, C2, and C3. The C-series fragments encompassed the region of
homology between BNIP-2 and Cdc42GAP (26, 27), which we termed BCH domain. The recombinants were expressed in E. coli,
purified, and used to precipitate HA-Cdc42 expressed in 293T cells, as
described under "Materials and Methods." The precipitated protein
was separated by SDS-PAGE followed by Western blotting using HA
antibody as the probe. Fig. 1B shows that the recombinant
full-length BNIP-2 bound Cdc42 relatively strongly and that this
interaction was mainly mediated via the C2 and C3 regions of BNIP-2.
Some weaker binding could be seen with fragment A, but no interaction
was detectable with the other regions of the molecule. To further demonstrate specificity of binding, two endogenous cellular proteins were assessed for their binding to the fragments of BNIP-2. It can be
seen in Fig. 1B (Crk, Lyn, and GST)
that neither the Crk adaptor protein nor the Lyn tyrosine kinase bound
any of the BNIP-2 fragments. Similarly, no binding by these fragments
could be seen when the phosphotyrosine phosphatase SHP-2 was
overexpressed in these cells (data not shown). The blot was stripped
and reprobed with anti-GST to reveal the integrity of these
recombinants and to show equal loading. To further demonstrate that the
BCH fragment of BNIP-2 could bind Cdc42, a precipitation experiment was
performed. A GST recombinant of BNIP-2 BCH was generated and used to
precipitate Cdc42 expressed in 293T cells. Their ability to
co-precipitate was compared with the GST recombinants of full-length
BNIP-2, Cdc42GAP, and GST beads alone. The results in Fig.
1C show that the BNIP-2 BCH binding to Cdc42 was equivalent
to or greater than that by the full-length BNIP-2 and of Cdc42GAP.
Molecular Modeling of the BCH Domain--
When BNIP-2 was first
cloned and sequenced, it was found to have a domain that was conserved
in only one other mammalian protein, an apparently noncatalytic
sequence found on the amino-terminal half of Cdc42GAP (27). It could be
assumed that BNIP-2 and Cdc42GAP might bind to a common substrate by
means of their shared BCH domain. Indeed, multiple sequence alignment
was recently presented that suggested that the BCH domain might be a
phospholipid-binding domain similar to that of the Saccharomyces
cerevisiae phosphatidylinositol transfer protein Sec14p (29).
However, there is only a low degree of homology apparent with these two
proteins. We demonstrated that the BCH domain mediates both hetero- and
homophilic binding of the proteins containing this sequence, which
would indicate that the BCH domain is likely to be a protein-protein
interaction domain.2 Further
alignment studies, however, indicated that the BCH domain was not
confined to two known mammalian proteins but has been highly conserved
throughout evolution, having been found also in two recently cloned but
uncharacterized proteins from Arabidopsis thaliana (Fig.
2A).
Because the BCH domain is found as a discrete homologous protein domain
highly conserved in sequence throughout evolution, it is plausible that
the BCH domain of BNIP-2 could form a functional and structural domain
with GAP activity toward Cdc42. In order to perform mutational
experiments to address this possibility, we need to know what residues
are most likely to be involved in the catalysis and binding. As we
currently lack a crystal structure of the complex, we decided to make
some testable assumptions using molecular modeling techniques.
Most GAPs have well defined structure and substrate specificities, as
exemplified by RasGAP, RanGAP, and RhoGAP acting only on Ras, Ran, and
Rho respectively. To date, structures of two RhoGAP domains binding to
Cdc42 have been identified, one for the catalytic GAP domain of
Cdc42GAP (16, 19, 21) and the other one for the BH domain of the
phosphoinositide 3-kinase p85 Identification of Candidate Residues Important for BNIP-2 GAP
Activity--
Based on the model above, we first sought to identify
candidate residues that might be important in mediating BNIP-2 GAP
activity. We assumed that these residues would fulfill the criteria as
listed below with respect to the known structure and the biochemistry of the GAP domains of Cdc42GAP. The two GAP domains that have been
described achieve catalysis either via an arginine finger (Cdc42GAP) or
via a conserved arginine patch (found in Cdc42, Rac1, RhoG, and RhoC
homodimers). Both arginine-containing sequences must be positioned on
the outside of the three-dimensional structure of the protein.
According to our model, there was no obvious region on BNIP-2 that
corresponded to the reactive arginine finger Arg-305 of Cdc42GAP. We
noted, however, a polybasic patch prominently displayed on the exterior
of the protein model corresponding to a region containing Arg-235,
Arg-236, and Arg-238 (as indicated in Fig. 2C). Somewhat
surprisingly, this region matches a reactive arginine motif recently
identified in the human Cdc42, Rac1, RhoC, and RhoG homodimers (Fig.
2D). Although not required for the formation of dimers, this
polybasic patch in these members of the Rho subfamily was identified to
be responsible for the GAP-like activity when homodimers were formed
(24, 25). Of particular interest is that in this local alignment, the
Arg-238 in BNIP-2 aligns to the critical arginine residue (Fig.
2D, arrow) that is indispensable for their GAP activities.
It is notable that this arginine residue is absent from those members
of the Rho family (and the BCH domain of Cdc42GAP) that lack the GAP activity.
We next mutated individual arginine residues to lysine to form R235K,
R236K, and R238K and tested whether they contribute to the GAP-like
catalytic activity of BNIP-2 on Cdc42. Each of these mutations was
introduced into the full-length BNIP-2 and expressed in vivo
in mammalian 293T cells. Lysates from control and transfected cells
were then tested for their ability to catalyze the GTP-hydrolysis of
GST-Cdc42 preloaded with [
Although each of these point mutations showed varying inhibitory
effects on the rates of GTP-hydrolysis, none was completely inactive
toward Cdc42, consistent with the notion that multiple residues are
involved in the GAP activity. To ensure that the loss in the GAP
activity by these mutants was not simply due to a loss of binding to
the partner protein or by misfolding of the recombinant protein, we
used GST-Cdc42 to test the binding to these mutants from the cell
lysates in precipitation experiments. Fig. 3B shows that
each of the mutants was soluble and that they had equal levels of
expression in 293T cells. When subjected to precipitation experiments,
each of the point-mutants exhibited an apparently equal affinity to the
GTP-loaded GST-Cdc42. This indicates that the overall structural
integrity of the BNIP-2 point mutants was maintained and that these
putative catalytic arginine residues were unlikely to be directly
involved in binding.
To further confirm that the BCH domain of BNIP-2 itself can fold
separately and act effectively as a GAP, various BCH GST recombinants
with or without the above point mutations were generated, purified, and
used in GAP assays (Fig. 4A).
Consistent with the full-length studies involving either BNIP-2
expressed in vivo, or in vitro, the recombinant
BCH of BNIP-2 alone could stimulate the rate of GTP hydrolysis of Cdc42
by 10-fold. Again, the GAP-like activity associated with the BNIP-2 BCH
domain was severely impaired by the R238K and R235K mutants and less
severely by the R236K mutant. In contrast, the homologous BCH domain of
Cdc42GAP was completely inactive toward Cdc42, although it can also
bind Cdc42 (data not shown). To ensure that the integrity of these
bacterially expressed recombinants remained intact, they were tested
for binding HA-Cdc42 in precipitation experiments (Fig. 4B).
The results show that none of the binding to Cdc42 had been compromised
and again demonstrate that these residues are important in the
catalysis but not for the binding.
Binding Regions within BCH and Cdc42--
Most
effectors/regulators of Cdc42 bind to the Switch I region (effector
binding domain) and/or the Rho family-specific "Insert" region
(31). We had previously generated Cdc42 recombinants with the
amino-terminal half containing the Switch I and Switch II regions, and
the carboxyl-terminal half of the Cdc42 containing the Insert region.
We found that either half of the molecule could bind to BNIP-2,
suggesting that there are multiple sites of binding on Cdc42 for BNIP-2
(data not shown). In order to delineate the sites of interaction
further, small deletion mutants of the Switch I (amino acids 32-40;
To test the various interactions, the wild-type or deletion constructs
of HA-BNIP-2 (
Contrary to the requirement for multiple regions of binding to Cdc42 by
BNIP-2, as demonstrated above, deletion of the Switch I region alone in
the GTP
It was shown previously that in the Ras·RasGAP complex (32) the
Gly-12 residue in the Switch I region of the GTPase contacts part of
the GAP closely. Mutation of this residue to valine (G12V) significantly reduced the binding of RasGAP to Ras (32, 33). We
hypothesized that the BCH domain of BNIP-2 would have a similar recognition profile. To test this hypothesis, HA-Cdc42 constructs were
expressed in 293T cells either as the wild-type, G12V, or T17N point
mutations, and each was subjected to precipitation experiments using
GST recombinants of either the full-length BNIP-2 or the BCH domain of
BNIP-2. The results in Fig. 5C show that the full-length
BNIP-2 and the BCH domain of BNIP-2 recognize wild-type Cdc42 readily
and in each case increased binding to the T17N mutant was apparent.
However, their binding to the G12V mutant was greatly diminished.
The loss of BCH binding to the G12V mutant is analogous to the decrease
of RasGAP binding to the G12V mutant of Ras. In the latter case, the
mutation did not change the overall structure of the molecule, but it
resulted in a reduced flexibility in the loop 4 region for proper
conformational change, particularly around the Gly-60 and Gln-61
residues, both of which are involved in We have identified several arginines as key residues within the
BNIP-2 BCH domain that are responsible for the GAP activity of the
protein. This region containing the arginines bears no similarity to
the arginine motifs employed by the "cradle-fold" structural
topology in the RasGAP or Cdc42GAP/RhoGAP catalytic structures (3,
14-22) or to the leucine repeat folds of RanGAP binding to Ran (23).
It does, however, show a striking similarity to the polybasic carboxyl
terminus of Cdc42. Although not required for the formation of dimers,
this polybasic patch in Cdc42 was identified to be responsible for its
GAP-like activity when homodimers are formed (24, 25). Of particular
interest is that in this local alignment, the Arg-238 in BNIP-2 matches
the critical arginine residue that is indispensable for the
homodimer-enhanced GAP activity. In those members of the Rho subfamily
that fail to display GAP activity when homodimerized, i.e.
RhoA and the yeast form of Cdc42 (25), this arginine is absent, as it
is from the BCH domain of Cdc42GAP, which is also catalytically
inactive (Fig. 2D). Although it lacks GAP activity, the BCH
domain of Cdc42GAP can still bind to Cdc42 (data not shown).
Despite the varying degrees of the loss of GAP activity displayed by
the R238K, R235K, and R236K mutants, BNIP-2 still retains its ability
to bind Cdc42, indicating that these residues are not involved in the
binding to Cdc42. The conserved arginine fingers in the GAP domains of
Cdc42GAP (34) or RasGAP (18, 35) have all been shown to be important
for catalysis and not for binding to their respective partners. In both
Cdc42GAP and RasGAPs, catalytic enhancement is likely to be the result
of stabilization of the conformation most complementary to the
transition state and from ground state destabilization (3, 14-22,
34-37). It is most likely that the reactive "arginine patch" in
BNIP-2 would confer one or more of the residues in-trans for
the catalysis. In this regard, we observed that Arg-235 and Arg-238 are
potent residues. The current work utilizes semiquantitative
measurements to demonstrate the involvement of such arginine fingers in
the BCH domain of BNIP-2. The actual relative contribution from each
arginine residue or combination of arginines 235, 236, and 238 awaits a
more thorough kinetic determination.
In some of the most efficient phosphoryl-transferring enzymes, such as
adenylate kinase and uridylate kinase (38, 39), several arginine
residues are located in the active sites and they catalyze the reaction
by stabilizing developing negative charges in the transition state.
Although the involvement of multiple neighboring polybasic residues had
not been tested in the similar arginine patches in Cdc42 and other Rho
family members, it is tempting to speculate that these tandem arginine
residues in BNIP-2 would provide a positive-charge interface to
stabilize the negative charges that develop during the transition state
of GTP hydrolysis in Cdc42. In Cdc42GAP, the Arg-305 within the
classical GAP domain has been identified both structurally and
biochemically as the key catalytic residue in promoting GTP hydrolysis
in Cdc42. It does not account, however, for the full GAP activity.
Recently, its adjacent arginine residue, Arg-306, was identified to be
necessary to further augment its GAP activity (40). Similarly, the
p120-RasGAP and the other RasGAP, neurofibromin NF1, both require at
least the input of Arg-789 and Arg-903 (for p120-RasGAP (17, 41)) or
Arg-1276 and Arg-1391 (for NF1 (42)) for optimal catalysis. Therefore,
it appears that although the BCH domain of BNIP-2 shows no clear
sequence homology to any of these molecules, it too could utilize the
same means to facilitate GTP hydrolysis by Cdc42.
Recently, evidence has begun accumulating that demonstrates that
various GTPases are the preferred eukaryotic substrates of diverse
bacterial toxins and exoenzymes (43-45). Several of these bacterial
products have been shown to interfere with Rho family GTPase activity
by means of chemical modifications on important residues (46, 47) or
increasing the lifetime of the active GTP-bound form of the Rho
proteins (48). Recently, the amino-terminal domain of Pseudomonas
aeruginosa exoenzyme S was shown to activate the GTPase activity
of Rho, Rac, and Cdc42 (45). It was interesting to note that the
catalytic domain on this protein had no strong sequence homology to any
canonical Rho-GAPs, thus providing evidence that dissimilar primary
sequences are capable of performing a similar catalytic function when
folded in the appropriate conformation.
Based on modeling, we attempted to identify the candidate regions for
interaction between BNIP-2 and Cdc42. We observed that at least three
sites on each protein are involved in interprotein binding. We showed
that the region 288EYV290 on BNIP-2 together
with the Switch I or Insert region of Cdc42 synergistically caused a
50% loss in binding, suggesting that they include at least three of
these binding sites. These data differ from those derived from studies
on the "classical" GAP domain of Cdc42GAP, in which deletion of the
Switch I region on Cdc42 alone was already sufficient to markedly
reduce the binding to this domain.
More than 10 direct interacting partners of Cdc42 have been identified
to date (Ref. 26 and references therein). It remains a major issue as
to how the incoming signals determine the specificity of functional
coupling between this molecule and its effectors/regulators. Recently,
Li et al. (49) utilized a mutational and chimeric approach
and mapped unique regions on Cdc42 responsible for binding to three
different target proteins. They showed that the Switch I and the
immediate neighboring region on Cdc42 contain all the necessary
determinants for PAK1 binding, whereas WASP and IQGAP1 did not bind the
same sequence. Two distantly located regions on Cdc42, residues
155-184 and residues 83-120, constitute the WASP- and IQGAP1-binding
regions, respectively. Furthermore, it was shown that the Rho
family-unique Insert region of Cdc42 is dispensable for PAK1 and WASP
binding but is required for high affinity binding by IQGAP1. Recently,
solution structures for the complex of Cdc42 binding to ACK (50) and
Cdc42 binding to WASP (51) have highlighted the involvement of unique
regions within Cdc42 and the respective effectors in mediating the
specificity in the binding. Our results show that the binding of BNIP-2
to Cdc42 was mainly mediated by the Switch I and the Insert region. It
will be interesting to test how BNIP-2 affects the binding of other
effectors to Cdc42 and to what extent this would affect cellular
functions. We have recently shown that BNIP-2, when
tyrosine-phosphorylated, failed to bind Cdc42 (26). This
phosphorylation could conceivably act as an additional switch to
regulate the formation/dissociation of the complex.
Based on our model, the BCH domain of BNIP-2 was predicted to display
folding similar to that of the classical GAP domain of Cdc42GAP.
Nevertheless, the refined structure is likely to be different from that
of the predicted structure. As noted previously, BNIP-2 binds equally
well to each form of Cdc42, whereas Cdc42GAP recognizes only the GDP or
GTP-bound form of Cdc42 (26, 52). This difference in binding
selectivity is further supported by our observations that a deletion in
the Switch I region of Cdc42 caused severe loss of binding to Cdc42GAP
but not to BNIP-2, suggesting that this region alone is not sufficient
to confer tight binding to BNIP-2.
The identification of the BCH domain as a binding domain for Cdc42 in
BNIP-2 and Cdc42GAP has further implications. Whereas the BCH domain of
BNIP-2 acts as a GAP, the corresponding region in Cdc42GAP does not,
partly because of its lack of Arg-236 and Arg-238 (see Fig.
2D). This raises an interesting issue as to what role this
region may play in the physiological function of Cdc42GAP. Most
previous biochemical and functional studies involving the interaction
of various GAPs with their binding partners were performed using the
minimal GAP domains, and any potential regulation via the non-GAP
domains would have been overlooked. We have evidence that suggests that
the BCH domain is also involved in homophilic and heterophilic
interactions involving BNIP-2 and Cdc42GAP. The discrete regions that
mediate these interactions are different from those involved in the
binding to Cdc42.2 It therefore seems likely that, because
of this binding specificity, this domain will have some regulatory function.
In conclusion, our present work has shown that the BCH domain of BNIP-2
define a new catalytic GAP domain that contains an arginine patch
similar to that found in certain members of the Rho subfamily when they
form homodimers. Although the actual mechanism of GAP catalysis by
either BNIP-2 or Cdc42 has yet to be determined by x-ray or NMR
structural analyses, current evidence suggests that strategically
placed arginine residues may represent GAP domains in different primary
sequences and tertiary structures. This notion is supported by the
recent identification of the arginine finger of rna1p/RanGAP present in
a novel folding structure that is mediated by leucine-rich repeats
(23).
-helical bundles similar to the topology of the catalytic
GAP domain of Cdc42GAP. Alignment of exposed arginine residues in this
domain helped to identify Arg-235 and Arg-238 as good candidates for
catalysis. Arg-238 matched well to the arginine "finger" required
for enhanced GTP hydrolysis in homodimerized Cdc42. Site-directed
mutagenesis confirmed that an R235K or R238K mutation severely impaired
the BNIP-2 GAP activity without affecting its binding to Cdc42. From
deletion studies, a region adjacent to the arginine patch
(288EYV290 on BNIP-2) and the Switch I and Rho
family-specific "Insert" region on Cdc42 are involved in the
binding. The results indicate that the BCH domain of BNIP-2
represents a novel GAP domain that employs an arginine patch
motif similar to that of the Cdc42-homodimer.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
was used as host for propagation of the clones. Reagents used
were of analytical grade, and standard protocols for molecular
manipulations and media preparations were from Ref. 53.
S) (Sigma) as described previously (26). Samples were run in
SDS-PAGE gels and analyzed by Western blotting with HA antibody (Roche Molecular Biochemicals) or FLAG antibody (Sigma).
-32P]GTP prebound to the molecule. GST-Cdc42 (5 µg)
still conjugated to the Sepharose beads, were washed twice in Buffer A
(50 mM HEPES, pH 7.4, 0.5 mM EDTA), and
resuspended in final 10 µl of the same buffer with 5 µCi of
[
-32P]GTP (6,000 Ci/mmol; New England Nuclear) for 10 min at room temperature. The reaction was terminated by adding 25 mM magnesium chloride. Excess unincorporated radioactive
GTP was removed by washing the beads five times in 1 ml of cold Buffer
B (50 mM HEPES, pH 7.4, 150 mM sodium chloride,
1.5 mM magnesium chloride, 5 mM EGTA, 10%
(v/v) glycerol, 1% (v/v) Triton X-100, a mixture of proteases
inhibitors, and 5 mM sodium orthovanadate). The beads were
finally resuspended in 10 µl of the same buffer. For in
vitro GAP assays using proteins expressed in bacteria, eluted
recombinants of BNIP-2 (1 µg in 100 µl of Buffer B) were then added
to the beads suspension and mixed well. The suspension was quickly
centrifuged to collect the beads and incubated at room temperature for
the times indicated, and aliquots of the supernatant (10 µl) were then taken for counting in a scintillation counter. For GAP assays involving 293T lysates, cells transfected with BNIP-2 (wild-type or
mutants) were lysed in Buffer B. A 20-µl of this lysate
(approximately 40 µg of total protein contents) was diluted in 100 µl of Buffer B before added to the GST-Cdc42 beads preloaded with
[
-32P]GTP and assayed, as described above.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (32K):
[in a new window]
Fig. 1.
The carboxyl terminus of BNIP-2 binds
Cdc42. A, defined are regions of BNIP-2 used in the
production of GST recombinants in E. coli as described under
"Materials and Methods." B, GST recombinants from
A were used to precipitate lysates of 293T cells transfected
with expression vector for HA-Cdc42. The associated proteins were
separated on SDS-PAGE, blotted, and probed with HA antibody (top
panel). The same blot was stripped and sequentially probed for Crk
(second panel from top), Lyn (third panel from
top) or GST (bottom panel). WCL, whole cell
lysates. C, 293T cells were transfected with (+) or without
(-) expression vectors for HA-Cdc42 and equal amounts of lysates were
used in the precipitation experiment with either GST alone or other GST
recombinants as indicated. Bound proteins were separated by SDS-PAGE,
blotted, and probed with HA antibody. FL, full-length
BNIP-2; BCH, BCH domain of BNIP-2; GAP, catalytic
domain of Cdc42GAP.

View larger version (72K):
[in a new window]
Fig. 2.
Modeling of the BCH domain and the putative
arginine finger. A, sequence alignment of the BCH
domains of BNIP-2 and Cdc42GAP with two putative proteins from A. thaliana containing BCH-like domains. The GenBankTM
accession numbers of Arab1 and Arab2 are AL031986 and AC009400,
respectively. B, sequence alignment of the BCH domains of
BNIP-2 and Cdc42GAP with the catalytic GAP domain of Cdc42GAP and the
BH domain of phosphoinositide 3-kinase p85
subunit. The conserved
-helices corresponding to the GAP domain of Cdc42GAP (19) are
depicted as bars on top of the sequences.
Numbers corresponding to the residues in each sequence are
shown on the right. GenBankTM accession numbers
for p85, Cdc42GAP, and BNIP-2 are P27986, Z23024, and U15173,
respectively. C, predicted structure of BNIP-2 BCH. The solvent-accessible molecular surfaces are rendered as a field of
connected gray dots. Inside the surface is a ribbon
representation, with helices colored red, and loops colored
light blue. On the surface, yellow dotted lines
define the region corresponding to the arginine patch (Arg-235,
Arg-236, and Arg-238) and the region containing
288EYV290. The side chains of these residues
are shown as spacefill and colored blue for basic,
yellow for polar, and gray for hydrophobic
residues. D, alignment of the arginine patch of BCH domain
with the putative arginine finger motifs of Rho. Asterisks
indicate the Rho proteins that have the active arginine residues
important for their GAP activity (arrow). Black, dark
gray, and light gray shading refers to 100, 80, and
60% sequence similarity, respectively. Hs, Homo
sapiens; Sc, S. cerevisiae.
Numbers refer to the residue positions of BNIP-2.
subunit (30). Although it binds to
Cdc42, the BH domain fails to act as a functional GAP for Cdc42. We
therefore set out to test whether the BCH domain, which also acts on
Cdc42, would have a structure similar to these domains. To test this
hypothesis, we predicted and modeled the tertiary structure of the BCH
domain. First, we aligned the BCH domains of BNIP-2 and Cdc42GAP to the canonical GAP domain of Cdc42GAP and the BH domain of p85
. Both the
GAP domain of Cdc42GAP and the BH domain of p85
have similar structural folds (16, 19, 21, and 30). The alignment shows considerable conservation in regions corresponding to the secondary structural elements (
-helices) of the GAP domain or the p85-BH domain (Fig. 2B). We then used the structures of the Cdc42GAP "GAP"
domain and the p85-BH domain as structural templates to model the BCH domain using the homology modeling techniques described under "Materials and Methods." The predicted structure (Fig.
2C) was used as a basis for the design of site-directed
mutagenesis and deletion experiments. Our assumption was that if the
BCH domain folds into the predicted GAP-like structure and binds to
Cdc42 in a manner similar to the catalytic GAP domain, we could use the
model to facilitate the identification of BCH residues and regions
involved in (a) GAP catalytic activity and (b)
binding to Cdc42.
-32P]GTP, as described under
"Materials and Methods." Fig.
3A shows that the intrinsic
GTPase activity of Cdc42 followed a linear time course over 30 min and
showed minimal catalytic activity under the conditions studied. This
activity was enhanced over 10-fold in the presence of wild-type BNIP-2.
Interestingly, mutations of the prime candidate arginine, Arg-238, as
well as Arg-235 markedly reduced the enhanced GAP activity toward
Cdc42. In comparison, the R236K mutant showed a GAP-like activity that
was 50% of that of wild-type BNIP-2. We also generated corresponding
mutants as full-length GST recombinants in bacteria to test their
effects on GTP hydrolysis in vitro. Results similar to those
in Fig. 3A were obtained, verifying that these BNIP-2
mutants had significantly lost the ability to enhance the GTP
hydrolysis of Cdc42 (data not shown).

View larger version (22K):
[in a new window]
Fig. 3.
Effect of arginine-to-lysine mutations on the
GAP activity of BNIP-2 expressed in vivo.
A, 293T cells were transfected with control vector
(open circles) or with expression vectors for the
full-length HA-BNIP-2: wild-type (filled circles), R235K
(filled triangles), R236K (filled squares), and
R238K (open triangles). Lysates were used in assays with
recombinant Cdc42 that was preloaded with radiolabeled GTP as described
under "Materials and Methods." B, lysates from
A were used in a pulldown experiment with equal amounts of
GST-Cdc42 preloaded with GTP
S, and bound proteins were separated by
SDS-PAGE, blotted, and probed with HA antibody (upper
panel). The same blot was stripped and probed for GST to
demonstrate equal loading (lower panel) WT,
wild-type.

View larger version (19K):
[in a new window]
Fig. 4.
The BCH domain of BNIP-2 confers GAP
activity. A, GST recombinants for the BCH domain of
BNIP-2 (either as the wild-type (WT) or as mutant R235K,
R236K, or R238K) were produced, eluted, and used to determine their GAP
effect on the GTP hydrolysis of Cdc42 preloaded with radiolabeled GTP
as described under "Materials and Methods." The activity was
expressed as the fold increase over the control using GST alone.
Results are means ± S.D. of three replicate determinations.
B, 293T cells were transfected with expression vector for
HA-Cdc42, and equal amounts of lysates were used in precipitation
experiments using the GST recombinants from A. Bound
proteins were separated by SDS-PAGE, blotted, and probed with HA
antibody.
SI), Switch II (amino acids 60-70;
SII), or the Insert region
(amino acids 89-94;
Ins) were generated. These deletion mutants
were then used to test for binding to either the wild-type BNIP-2 or
the BNIP-2 deletion mutant,
T, that is devoid of residues
288EYV290. This region is located on the outer
surface and is potentially involved in binding Cdc42 as predicted from
our model above (Fig. 2C). As a control, we deleted the
235RRLRK239 region (
R) in BNIP-2, assumed by
modeling and experimental data (shown above) to be important for
catalysis and not for binding.
R or
T) were expressed in 293T cells, and the
lysates were subjected to precipitation experiments with GTP
S-bound
GST-Cdc42, either as the wild-type or with deletions in the Switch I,
Switch II, or Insert region. The results in Fig. 5A show that each of the
HA-BNIP-2 wild-type or mutants was expressed equally well in 293T cells
(see WCL), and none of them bound the controls with GST beads alone.
The binding by the wild-type BNIP-2 was not significantly affected by
any single deletion on Cdc42 (Fig. 5A, compare
results in lane 1). This confirmed our previous observation
that there exist multiple sites of interaction on Cdc42 for BNIP-2.
Similar results were seen when the proposed catalytic domain of BNIP-2
was deleted (lane 2). However, when the BNIP-2
T mutant
was used as the target (lane 3), there was nearly a 50%
loss in its binding to the Cdc42 mutants lacking either the Switch I
region or the Insert region. No effect was seen in the binding of this
T mutant to the wild-type Cdc42 or its Switch II deletion mutant.
The apparent synergistic effect that deletions of region T have with
Switch I or the Insert would be consistent with the notion that region
T does not interact directly with either the Switch I or the Insert. A
similar degree in the loss of binding would have been seen by either
single or combined deletions of these constructs if region T was
binding to either the Switch I or Insert. This means that the Switch I and the Insert region of Cdc42 would both contribute to the binding to
two distinct but unknown regions on BNIP-2, whereas the region T
(encompassing 288EYV290) on BNIP-2 would
represent another site of interaction with other region(s) of
Cdc42.

View larger version (29K):
[in a new window]
Fig. 5.
Binding regions on Cdc42 and BNIP-2.
A, 293T cells were transfected with expression vectors for
HA-BNIP-2 either as the wild-type (lane 1), deletion mutant
R (lane 2), or deletion mutant
T (lane 3)
as described in text. Lysates were then used in precipitation
experiments using GST-Cdc42, wild-type (WT), or deletions in
the regions of Switch I (
SI), Switch II (
SII), or the Rho
family-specific Insert (
Ins), all of which were preloaded with
GTP
S prior to precipitation experiments as described under
"Materials and Methods." Bound proteins were separated in SDS-PAGE,
blotted, and probed with HA antibody. Aliquots of lysates from
A were analyzed for the equal expression of HA-BNIP-2
proteins by HA Western analysis, indicated as whole cell lysates
(WCL), and also tested for nonspecific binding to the GST
beads alone. B, 293T cells were transfected with expression
vector for FLAG-Cdc42GAP, and equal aliquots of lysates were used in
precipitation experiments using the GST-Cdc42 wild-type
(WT),
SI,
SII, or
Ins preloaded with GTP
S, as in
A. Bound proteins were separated in SDS-PAGE, blotted, and
probed with FLAG antibody. C, 293T cells were transfected
with expression vectors for HA-Cdc42 as either the wild-type
(lanes 1), G12V mutant (lanes 2), or T17N mutant
(lanes 3). Lysates were used in precipitation experiments
using GST recombinants of either the full-length BNIP-2 (FL)
or the BCH domain of BNIP-2 as indicated. Bound proteins were separated
by SDS-PAGE, blotted and probed with HA antibody. Aliquots of whole
cell lysates were probed with HA antibody to determine the equal
expression of the HA-tagged wild-type or mutant Cdc42.
S-bound form of Cdc42 could reduce its binding to Cdc42GAP by
two-thirds, whereas deletions of the Switch II or the Insert region had
no effect on the binding (Fig. 5B). The direct involvement
of the Switch I but not the Insert region of Cdc42 in binding Cdc42GAP
is consistent with the crystallographic structure of the complex (15).
However, we were surprised that deletion of the Switch II region had
minimal effects on Cdc42 binding to Cdc42GAP, when similar studies had
shown it to be a likely interacting sequence (15).
-phosphate binding and the
enzymatic reaction (32). These results indicate that the BCH domain of
BNIP-2 assumes a high degree of sensitivity toward some of the
conformational changes in Cdc42 in a manner similar but perhaps not
identical to that of the canonical GAPs.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Catherine Pallen, Dr. Permeen Yusoff, and Jormay Lim for constructive criticism and help in reading the manuscript. We are also grateful to Dr. Alan Hall for the generous donation of materials.
| |
FOOTNOTES |
|---|
* This work was supported by the Institute of Molecular and Cell Biology, National University of Singapore.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 65-874-3737;
Fax: 65-779-1117; E-mail: mcbgg@imcb.nus.edu.sg.
2 B. C. Low, K. T. Seow, and Graeme R. Guy, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
GAP, GTPase-activating protein;
BCH, BNIP-2 and Cdc42GAP homology;
BH, breakpoint cluster region homology;
GST, glutathione
S-transferase;
GTP
S, guanosine
5'-3-O-(thio)triphosphate;
HA, hemagglutinin;
PAGE, polyacrylamide gel electrophoresis.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Lamarche, N., and Hall, A. (1994) Trends Genet. 10, 436-440[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Kjoller, L., and Hall, A. (1999) Exp. Cell Res. 253, 166-179[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Scheffzek, K., Ahmadian, M. R., and Wittinghofer, A. (1998) Trends Biochem. Sci. 23, 257-262[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Chant, J., and Stowers, L. (1995) Cell 81, 1-4[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Hall, A.
(1998)
Science
279,
509-514 |
| 6. | Hall, A. (1999) Br. J. Cancer 80 Suppl 1, 25-27 |
| 7. | Chardin, P., Boquet, P., Modaule, P., Popoff, M. R., Rubin, E. J., and Gill, D. M. (1989) EMBO J. 8, 1087-1092[Medline] [Order article via Infotrieve] |
| 8. |
Paterson, H. F.,
Self, A. J.,
Garrett, M. D.,
Just, I.,
Aktories, K.,
and Hall, A.
(1990)
J. Cell Biol.
111,
1001-1009 |
| 9. | Waterman-Storer, C. M., Worthylake, R. A., Liu, B. P., Burridge, K., and Salmon, E. D. (1999) Nat. Cell Biol. 1, 45-50[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Kozma, R., Ahmed, S., Best, A., and Lim, L. (1995) Mol. Cell. Biol. 15, 1942-1952[Abstract] |
| 11. | Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Minden, A., Lin, A., Claret, F. X., Abo, A., and Karin, M. (1995) Cell 81, 1147-57[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Aspenstrom, P. (1999) Curr. Opin. Cell Biol. 11, 95-102[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Sprang, S. R. (1997) Curr. Opin. Struct. Biol. 7, 849-856[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Rittinger, K., Walker, P. A., Eccleston, J. F., Nurmahomed, K., Owen, D., Laue, E., Gamblin, S. J., and Smerdon, S. J. (1997) Nature 388, 693-697[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Nassar, N., Hoffman, G. R., Manor, D., Clardy, J. C., and Cerione, R. A. (1998) Nat. Struct. Biol. 5, 1047-1052[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Scheffzek, K.,
Ahmadian, M. R.,
Kabsch, W.,
Wiesmuller, L.,
Lautwein, A.,
Schmitz, F.,
and Wittinghofer, A.
(1997)
Science
277,
333-338 |
| 18. | Ahmadian, M. R., Stege, P., Scheffzek, K., and Wittinghofer, A. (1997) Nat. Struct. Biol. 4, 686-689[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Barrett, T., Xiao, B., Dodson, E. J., Dodson, G., Ludbrook, S. B., Nurmahomed, K., Gamblin, S. J., Musacchio, A., Smerdon, S. J., and Eccleston, J. F. (1997) Nature 385, 458-461[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Bax, B. (1998) Nature 392, 447-448[Medline] [Order article via Infotrieve] |
| 21. | Rittinger, K., Taylor, W. R., Smerdon, S. J., and Gamblin, S. J. (1998) Nature 392, 448-449[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Calmels, T. P., Callebaut, I., Leger, I., Durand, P., Bril, A., Mornon, J. P., and Souchet, M. (1998) FEBS Lett. 426, 205-211[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Hillig, R. C., Renault, L., Vetter, I. R., Drell, T., IV, Wittinghofer, A., and Becker, J. (1999) Mol. Cell 3, 781-791[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Zhang, B.,
and Zheng, Y.
(1998)
J. Biol. Chem.
273,
25728-25733 |
| 25. |
Zhang, B.,
Zhang, Y.,
Collins, C. C.,
Johnson, D. I.,
and Zheng, Y.
(1999)
J. Biol. Chem.
274,
2609-2612 |
| 26. |
Low, B. C.,
Lim, Y. P.,
Lim, J.,
Wong, E. S. M.,
and Guy, G. R.
(1999)
J. Biol. Chem.
274,
33123-33130 |
| 27. | Boyd, J. M., Malstrom, S., Subramanian, T., Venkatesh, L. K., Schaeper, U., Elangovan, B., D'Sa-Eipper, C., and Chinnadurai, G. (1994) Cell 79, 341-351[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Chen, C.,
Seow, K. T.,
Guo, K.,
Yaw, L. P.,
and Lin, S.-C.
(1999)
J. Biol. Chem.
274,
19799-197806 |
| 29. | Aravind, L., Neuwald, A. F., and Ponting, C. P. (1999) Curr. Biol. 9, 195-197 |
| 30. | Musacchio, A., Cantley, L. C., and Harrison, S. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 10, 14373-14378 |
| 31. | Feltham, J. L., Dotsch, V., Raza, S., Manor, D., Cerione, R. A., Sutcliffe, M. J., Wagner, G., and Oswald, R. E. (1997) Biochemistry 36, 8755-8766[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Krengel, U., Schlichting, L., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, W., Pai, E. F., and Wittinghofer, A. (1990) Cell 62, 539-548[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Al-Mulla, F., Milner-White, E. J., Going, J. J., and Birnie, G. D. (1999) J. Pathol. 187, 433-438[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Graham, D. L., Eccleston, J. F., and Lowe, P. N. (1999) Biochemistry 38, 985-991[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Geyer, M., Schweins, T., Herrmann, C., Prisner, T., Wittinghofe, A., and Kalbitzer, H. R. (1996) Biochemistry 35, 10308-10320[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Ahmed, S.,
Lee, J.,
Wen, L. P.,
Zhao, Z.,
Ho, J.,
Best, A.,
Kozma, R.,
and Lim, L.
(1994)
J. Biol. Chem.
269,
17642-17648 |
| 37. | Morcos, P., Thapar, N., Tusneem, N., Stacey, D., and Tamanoi, F. (1996) Mol. Cell. Biol. 16, 2496-2503[Abstract] |
| 38. | Abele, U., and Schulz, G. E. (1995) Protein Sci. 4, 1262-1271[Abstract] |
| 39. | Scheffzek, K., Kliche, W., Wiesmuller, L., and Reinstein, J. (1996) Biochemistry 35, 9716-9727[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Leonard, D. A.,
Lin, R.,
Cerione, R. A.,
and Manor, D.
(1998)
J. Biol. Chem.
273,
16210-16215 |
| 41. | Scheffzek, K., Lautwein, A., Kabsch, W., Ahmadian, M. R., and Wittinghofer, A. (1996) Nature 384, 591-596[CrossRef][Medline] [Order article via Infotrieve] |
| 42. |
Sermon, B. A.,
Lowe, P. N.,
Strom, M.,
and Eccleston, J. F.
(1998)
J. Biol. Chem.
273,
9480-9485 |
| 43. | Aktories, K. (1997) Trends Microbiol. 5, 282-288[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Fu, Y., and Galan, J. E. (1999) Nature 401, 293-297[CrossRef][Medline] [Order article via Infotrieve] |
| 45. |
Goehring, U.-M.,
Schmidt, G.,
Pederson, K. J.,
Aktories, K.,
and Barbieri, J. T.
(1999)
J. Biol. Chem.
274,
36369-36372 |
| 46. |
Sekine, A.,
Fujiwara, M.,
and Narimuya, M.
(1989)
J. Biol. Chem.
264,
8602-8605 |
| 47. | Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503[CrossRef][Medline] [Order article via Infotrieve] |
| 48. |
Horiguchi, Y.,
Inoue, N.,
Masuda, M.,
Kashimoto, T.,
Katahira, J.,
Sugimoto, N.,
and Matsuda, M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11623-11626 |
| 49. |
Li, R.,
Debreceni, B.,
Jia, B.,
Gao, Y.,
Tigyi, G.,
and Zheng, Y.
(1999)
J. Biol. Chem.
274,
29648-27654 |
| 50. | Mott, H. R., Owen, D., Nietlispach, D., Lowe, P. N., Manser, E., Lim, L., and Laue, E. D. (1999) Nature 399, 384-388[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Abdul-Manan, N., Aghazadeh, B., Liu, G. A., Majumdar, A., Ouerfelli, O., Siminovitch, K. A., and Rosen, M. K. (1999) Nature 399, 379-383[CrossRef][Medline] [Order article via Infotrieve] |
| 52. |
Lancaster, C. A.,
Taylor-Harris, P. M.,
Self, A. J.,
Brill, S.,
van Erp, H. E.,
and Hall, A.
(1994)
J. Biol. Chem.
269,
1137-1142 |
| 53. | Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , pp. 1.53-1.85, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY |
| 54. |
Thompson, J. D.,
Higgins, D. G.,
and Gibson, T. J.
(1994)
Nucleic Acids Res.
22,
4673-4680 |
This article has been cited by other articles:
![]() |
U. J. K. Soh and B. C. Low BNIP2 extra long inhibits RhoA and cellular transformation by Lbc RhoGEF via its BCH domain J. Cell Sci., May 15, 2008; 121(10): 1739 - 1749. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Buschdorf, L. Li Chew, B. Zhang, Q. Cao, F.-Y. Liang, Y.-C. Liou, Y. T. Zhou, and B. C. Low Brain-specific BNIP-2-homology protein Caytaxin relocalises glutaminase to neurite terminals and reduces glutamate levels. J. Cell Sci., August 15, 2006; 119(Pt 16): 3337 - 3350. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Lua and B. C. Low Activation of EGF receptor endocytosis and ERK1/2 signaling by BPGAP1 requires direct interaction with EEN/endophilin II and a functional RhoGAP domain J. Cell Sci., June 15, 2005; 118(12): 2707 - 2721. [Abstract] [Full Text] [PDF] |
||||